Clinical trials: Alcohol Use Disorder, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition Alcohol Use Disorder
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Alcohol Use Disorder (AUD), Overweight or Obese
Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)
The investigators approach is to conduct a Phase II Double-Blind randomised controlled trial with individuals with co-occurring Alcohol Use Disorder and overweight/obesity (AUD-OOB) to receive either a sub-cutaneous injection of…
- Conditions
- Alcohol Use Disorder (AUD), Overweight or Obese, Comorbidities and Coexisting Conditions
- Trial name
- NCT07292519
- Testing
- Tirzepatide, Take Control CBT Module
- Where
- Australia
- Volunteers
- 46 people
- Sponsor
- South West Sydney Local Health District
Alcohol Use Disorder
Motivation for IV Alcohol Self-Administration in Humans
The goal of this translational study is to understand different reasons why people between the ages of 21 and 65 with alcohol use disorder are motivated to self-administer alcohol.
- Trial name
- NCT06494891
- Testing
- Intravenous Alcohol
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- University of California, Los Angeles
Alcohol Use Disorder (AUD)
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)
Background: Glucagon-like peptide 1 (GLP-1) agonist drugs are used to treat diabetes and aid weight loss. They may also help reduce cravings for drugs and alcohol.
- Trial name
- NCT07559500
- Testing
- Tirzepatide, [11C]raclopride plus drug, [11C]NNC-112
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use Disorder
The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking
The proposed project tests the efficacy of glutamate modulators in non-depressed individuals with alcohol use disorder (AUD); the primary hypothesis is that the glutamate modulator being tested reduces heavy drinking days…
- Trial name
- NCT04084860
- Testing
- CI-581a, CI-581b, MBRP
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- New York State Psychiatric Institute
Alcohol Withdrawal, Alcohol Abstinence
Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients
Alcohol withdrawal syndrome is a highly morbid condition affecting a substantial percentage of patients hospitalized who have alcohol use disorders, estimated at 5-6% of all hospitalized patients.
- Conditions
- Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
- Trial name
- NCT07810946
- Testing
- Sodium Acetate
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Colorado, Denver
Alcohol Use Disorder
Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)
Background: Phosphodiesterase-4B (PDE4B) is a protein in the brain that may play a role in several mental health disorders. Researchers want to know if drinking alcohol increases the binding of a radioactive tracer to PDE4B in…
- Trial name
- NCT07027839
- Testing
- Intravenous Ethanol, 18F-PF-06445974
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Mental Health (NIMH)
Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD)
Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL)
To assess the safety, feasibility and preliminary efficacy of ketamine-enhanced therapy (KET) for alcohol use disorder (AUD) and comorbid major depressive disorder (MDD) in an open-label, single arm, pilot clinical trial.
- Conditions
- Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD), Comorbidities and Coexisting Conditions
- Trial name
- KET-DUAL (NCT07247370)
- Testing
- Ketamine, Cognitive Behavioural Therapy
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- South West Sydney Local Health District
Alcohol Use Disorder, Addiction
Tdcs And cogNitive traininG cOmbined for AUD (TANGO)
The overarching goal of this project is to expand the traditional expertise in non-invasive neuromodulation at the University of Minnesota towards developing novel paired-neuromodulation approaches using transcranial direct…
- Trial name
- NCT05062369
- Testing
- TaskFlow Transcranial Electrical Stimulation device, Executive Function Focused Cognitive Training
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Minnesota
Alcohol Abuse/Dependence, Alcohol Use Disorder (AUD)
Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder
The goal of this clinical trial is to learn about the effects of the combination of ketamine and realtime functional magnetic resonance imaging (fMRI) neurofeedback training on the treatment of individuals with alcohol use…
- Conditions
- Alcohol Abuse/Dependence, Alcohol Use Disorder (AUD), Alcoholism
- Trial name
- Nektar (NCT06969937)
- Testing
- Ketamine, Real-time fMRI Neurofeedback Training
- Where
- Switzerland
- Volunteers
- 75 people
- Sponsor
- Dr. med. Marcus Herdener
Alcohol Use Disorder
Sex Differences in the Response to Abstinence From Alcohol.
In laboratory animals, repeated cycles of abstinence from and return to alcohol drinking can lead to changes in alcohol intake. In a study of the effect of abstinence on drinking in humans, the investigators found evidence that…
- Trial name
- SPAR (NCT03827460)
- Testing
- Abstinence from alcohol, Usual drinking, Intravenous Alcohol
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Indiana University
Alcohol Use Disorder
PET Imaging of Phosphodiesterase-4B (PDE4B) in Alcohol Use Disorder
Background: People with alcohol use disorder (AUD) also often have bouts of depression called major depressive episodes (MDEs). People having MDEs have been found to have low levels of a protein called PDE4B in the brain.
- Trial name
- NCT06795581
- Testing
- 18F-PF-06445974, Oxazepam
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Mental Health (NIMH)
Alcohol Use Disorder, Alcohol Use, Unspecified
Drinking, Acetate, and Stress
The purpose of this study is to learn how drinking alcohol affects how people experience stress and how that is affected by the body's chemistry.
- Conditions
- Alcohol Use Disorder, Alcohol Use, Unspecified, Heavy Drinker, Alcohol Use Disorder, Moderate, in Sustained Remission
- Trial name
- NCT06584448
- Testing
- Deuterium Metabolic Imaging with deuterated acetate tracer
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yale University
Depression - Major Depressive Disorder, Alcohol Use Disorder
ACT_for Alcohol Use Disorder and Depression
Alcohol use disorders (AUDs) and depressive disorders frequently coexist, complicating the clinical management of patients suffering from them.
- Trial name
- NCT06620276
- Testing
- Acceptance and Commitment Therapy, Ketamine
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Alcohol Use Disorder, Obesity and Overweight
Tirzepatide for Alcohol Use Disorder
The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or…
- Conditions
- Alcohol Use Disorder, Obesity and Overweight, Alcohol
- Trial name
- NCT06994338
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Southern California
Alcohol Use Disorder, Alcohol Abuse/Dependence
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for the treatment of type 2 diabetes and obesity, have shown promise as a novel treatment for alcohol use disorder (AUD).
- Conditions
- Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence, Alcoholism
- Trial name
- DUALPSYCHIATRY (NCT06939088)
- Testing
- Tirzepatide
- Where
- 2 sites in Denmark
- Volunteers
- 108 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Healthy Adult Male and Female Volunteers
Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol
Naltrexone (NTX), an opioid receptor antagonist, has a longstanding history of safe and effective use for the treatment of addictive disorders.
- Trial name
- NCT07269873
- Testing
- BICX104 naltrexone implantable pellet, Bupropion 150 mg XL, Naltrexone (depot)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BioCorRx Pharmaceuticals Inc
Alcohol Use Disorder (AUD), Alcohol Abstinence
SER-ABS-AUD: Neuropsychosocial-Spiritual Correlates of Serene Abstinence in Adults With AUD
SER-ABS-AUD is a single-centre, non-interventional, mixed retrospective-prospective longitudinal cohort study of 70 adults aged 18-70 years with documented alcohol use disorder, at least 12 consecutive months of continuous…
- Trial name
- SER-ABS-AUD (NCT07561749)
- Where
- Romania
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Alcohol Use Disorder (AUD)
Evaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use Disorder
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial. The study plans to enroll 240 adult patients with Alcohol Use Disorder (AUD).
- Trial name
- AUD (NCT07433413)
- Testing
- Naltrexone
- Volunteers
- 240 people
- Sponsor
- Shenzhen Sciencare Medical Industries Co., Ltd.
Alcohol Use Disorder
Spironolactone in Alcohol Use Disorder (SAUD)
Background: Alcohol use disorder (AUD) affects about 29.5 million people in the United States. Only 3 medicines have been approved by Food and Drug Administration to treat AUD. Researchers want to find better treatments for AUD.
- Trial name
- NCT05807139
- Testing
- Spironolactone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Alcohol Use Disorder
Emergency Department-Initiated Medications for Alcohol Use Disorder
The proposed study will be the first randomized clinical trial to evaluate a comprehensive Emergency Department (ED)-based intervention for moderate to severe Alcohol Use Disorder (AUD) combining Screening, Brief Intervention and…
- Trial name
- NCT05827159
- Testing
- Naltrexone Pill, Naltrexone Injection, Brief Negotiation Interview
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Yale University